Holen Sie sich die Stockscreener-App
5.32
3.10%
0.16
Handel nachbörslich:
5.32
Schlusskurs vom Vortag:
$5.16
Offen:
$5.17
24-Stunden-Volumen:
203.64K
Relative Volume:
1.20
Marktkapitalisierung:
$202.36M
Einnahmen:
$239.40M
Nettoeinkommen (Verlust:
$104.44M
KGV:
1.7973
EPS:
2.96
Netto-Cashflow:
$-18.50M
1W Leistung:
-10.59%
1M Leistung:
-18.78%
6M Leistung:
-57.88%
1J Leistung:
-66.35%
1-Tages-Spanne:
$5.133
$5.47
1-Wochen-Bereich:
$4.93
$5.95
52-Wochen-Spanne:
$4.93
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Vergleichen Sie TRDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
5.32 | 196.27M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Real time breakdown of Entrada Therapeutics Inc. stock performanceWeekly Trading Summary & Stock Portfolio Risk Management - Newser
Applying chart zones and confluence areas to Entrada Therapeutics Inc.IPO Watch & Weekly Chart Analysis and Trade Guides - Newser
Tools to assess Entrada Therapeutics Inc.’s risk profilePortfolio Gains Summary & Accurate Trade Setup Notifications - Newser
Is Entrada Therapeutics Inc. stock reversal real or fakeJuly 2025 Closing Moves & Safe Swing Trade Setup Alerts - Newser
Entrada Therapeutics Inc. recovery potential after sell offFree Long Hold Safe Return Strategy - Newser
How Entrada Therapeutics Inc. stock performs during market volatilityFree Accurate Buy Point for Momentum Stocks - Newser
Is Entrada Therapeutics Inc. meeting your algorithmic filter criteriaSmart Stock Forecast Using AI Algorithms - Newser
What makes Entrada Therapeutics Inc. stock price move sharplyTrading Opportunities Forecast by AI Insight - Newser
Measuring Entrada Therapeutics Inc.’s beta against major indicesBuy and Hold Position Summary Review - Newser
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates - 富途牛牛
HC Wainwright Issues Pessimistic Outlook for TRDA Earnings - Defense World
Roth Capital Issues Pessimistic Forecast for TRDA Earnings - Defense World
Why Entrada Therapeutics Inc. stock attracts strong analyst attentionWeekly Market Direction and Sector Summary - Newser
William Blair Issues Negative Forecast for TRDA Earnings - Defense World
Is Entrada Therapeutics Inc. stock bottoming outFree AI Screening for Swing Trade Picks - Newser
Entrada Therapeutics' Revenue Estimates Cut by 57% Amid Weaker Q1 Results - AInvest
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Entrada Therapeutics (NASDAQ:TRDA) Downgraded to Sell Rating by Wall Street Zen - Defense World
Live market analysis of Entrada Therapeutics Inc.Market Stability and Long-Term Growth Outlook - Newser
Sentiment analysis tools applied to Entrada Therapeutics Inc.Algorithmic Forecast for Swing Trading Picks - Newser
Roth/MKM lowers Entrada Therapeutics stock price target to $17 from $21 - Investing.com Canada
Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements - TipRanks
Entrada Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Entrada (TRDA) Q2 Revenue Drops 98% - AOL.com
Entrada Therapeutics 2025 Q2 Earnings Misses Targets with Net Loss Widens 178.3% - AInvest
Entrada Therapeutics Reports Q2 2025 Financial Results - TipRanks
Entrada Therapeutics Q2 Revenue Falls 98%, Losses Widen to $1.04 per Share - AInvest
Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
Entrada Therapeutics shares fall 1.01% after-hours after reporting a net loss of USD 43.1 million for Q2 2025. - AInvest
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Entrada Therapeutics Reports Q2 Loss, Misses Revenue Estimates, Shares Down 66.3% YTD - AInvest
Entrada Therapeutics August 2025 slides: advancing four clinical-stage programs - Investing.com Canada
Entrada Therapeutics earnings missed by $0.22, revenue fell short of estimates - Investing.com Canada
Entrada Therapeutics, Inc. SEC 10-Q Report - TradingView
Entrada Therapeutics Q2 collaboration revenue drops, net loss widens - MarketScreener
Entrada Therapeutics Reports Second Quarter 2025 Financial Results - Stock Titan
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics - TipRanks
Can volume confirm reversal in Entrada Therapeutics Inc.Pattern Recognition Based Market Move Prediction - Newser
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):